Madiha Ajaz

Dr. Madiha Ajaz

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Respiratory Medicine
Verified
Journal Article
Open access
MAMadiha Ajaz
Madiha Ajaz
ISIndu Singh
Indu Singh
LVLada Vugic
Lada Vugic
RJRati Jani
Rati Jani
HRHasini Rathnayake
Hasini Rathnayake
NCNatalie J. Colson
Natalie J. Colson
Asthma is a chronic inflammatory disease and a leading cause of disability, posing a huge economic and social burden. Plant-based antioxidants have the potential to block proinflammatory pathways and protect against oxidative damage, which could improve asthma management. This review examines the role of plant-based antioxidants as adjuvant therapy on inflammatory markers and clinical outcomes of adults with asthma. Digital databases, including Scopus, MEDLINE, EMBASE, CINAHL, PsycINFO, and Cochrane Airway Group's Specialized Register of Trials, were searched. Two independent authors performed initial and full-text screening of identified papers. The criteria for study inclusion and exclusion were predefined. Two authors independently performed data extraction and risk of bias as per the PRISMA checklist. After full-text screening, nine randomized controlled trials were included in the final review. Seven of the included studies highlighted the efficacy of plant-based antioxidants in modulating the inflammatory cytokines in asthmatics. The benefits of antioxidants were also observed for improving oxidative status, lung functioning, and airway inflammatory markers. Furthermore, the overall quality of asthmatic patients' lives was improved with fewer exacerbations such as night coughs and wheezing. Despite having some limitations, the overall risk of bias was low in this review. The review indicated that plant-based antioxidants could have adjuvant beneficial effects in the management of asthma inflammatory markers, which may help improve asthma-related clinical outcomes. However, due to the small number of study subjects, further research is required on the effect of plant-based antioxidants on asthma-inflammatory markers and clinical outcomes.

3 October 2024 in Current Nutrition Reports
Verified
Journal Article
Open access
PDF file
SDShashya Diyapaththugama
Shashya Diyapaththugama
GMGetahun Fentaw Mulaw
Getahun Fentaw Mulaw
MAMadiha Ajaz
Madiha Ajaz
NCNatalie Colson
Natalie Colson
ISIndu Singh
Indu Singh
RJRati JANI
Rati JANI
Purpose of Review: The miracle fruit contains the glycoprotein miraculin which can modify the taste perception of food and beverages at low pH conditions, altering the consumers’ food preferences. This review aims to critically evaluate all available evidence on miracle fruit/ miraculin and taste modification and its potential role in improving food preferences. Recent Findings: Miracle fruit suppresses sourness and induces sweetness in acidic food/ beverages. At low pH conditions, miracle fruit enhances the sweet taste and decreases the perceived intensities of salty and bitter tastes in solutions. However, the role of miracle fruit in sweet, salty, and bitter food is not adequately studied. The above effects alter the food-liking scores in individual foods and mixed diets. Summary: Miracle fruit is a pH-dependent taste modifier with the potential to be used in food applications to improve consumer food preferences. Future research on the changes in food preferences with the optimum miraculin dose, food type, and intrapersonal variations in taste sensitivity is warranted.

28 August 2025 in Food Frontiers
Verified
Journal Article
Open access
MAMadiha Ajaz
Madiha Ajaz
AZAyesha Zahid
Ayesha Zahid
HIHazrat Ismail
Hazrat Ismail
MAMisbah Ajaz
Misbah Ajaz
Otitis media (OM), a common infection of the middle ear, remains a leading cause of preventable hearing loss globally. Chronic inflammation underpins its pathophysiology, driving persistent mucosal damage and complications such as cholesteatoma. Key inflammatory mediators contribute to sustained neutrophilic infiltration and mucosal thickening, making them attractive therapeutic targets. Flavonoids, a diverse group of hydroxylated polyphenols with established anti‐inflammatory and antioxidant properties, have shown efficacy in a range of diseases, including cancer, metabolic disorders, and neurodegeneration. However, their potential role in modulating inflammation in OM has not been systematically explored. Here, we conducted a systematic review of rodent models of OM treated with flavonoids, adhering to PRISMA guidelines and searching PubMed, Scopus, Cochrane, MEDLINE, and CINAHL Complete. Outcomes included serum and mRNA expression of TNF‐α, IL‐1β, IL‐4, IL‐6, and VEGF, as well as neutrophil counts and mucosal thickness. Across studies, flavonoid treatment was associated with downregulation of pro‐inflammatory markers, reduced neutrophilic infiltration, and attenuation of mucosal thickening. These findings highlight the potential of flavonoids as adjunctive agents in OM, warranting further investigation into their mechanistic pathways and translational relevance.

12 February 2026 in Food Science & Nutrition
Verified
Journal Article
Open access
AYAlessandro Young
Alessandro Young
MAMadiha Ajaz
Madiha Ajaz
LVLada Vugic
Lada Vugic
NSNatalie Shilton
Natalie Shilton
Previous research has demonstrated the anti‐inflammatory effects of anthocyanin supplementation, as evidenced by reduced levels of inflammatory adipokines in obese populations. However, the relationship between anthocyanin intake and obesity‐related adipokines remains unclear in existing research. To investigate this, we hypothesised that anthocyanin supplementation would significantly reduce plasma concentrations of interleukin‐8 (IL‐8), IL‐18, interferon‐gamma (IFN‐γ) and resistin, and significantly increase plasma concentrations of IL‐10 in a healthy, overweight, and obese population. A systematic search of PubMed and Scopus was conducted between September 2024 and November 2024, resulting in 22 eligible studies for inclusion. The standardised mean difference was used to establish the effect size, and I‐squared was used to determine heterogeneity. The risk of bias was assessed using Cochrane's risk of bias assessment tool. An Egger's test and funnel plot were utilised to determine any publication bias. The meta‐analysis data showed that the inclusion of anthocyanins resulted in significant reductions in IL‐8 ( p = 0.004) and IFN‐γ ( p = 0.02). However, we observed that IL‐10 ( p = 0.97), IL‐18 ( p = 0.28) and resistin ( p = 0.42) did not show a significant effect after anthocyanin consumption. The findings indicate that anthocyanin supplementation can significantly decrease circulating plasma levels of IL‐8 and IFN‐γ in healthy, overweight, and obese populations, but not IL‐10, IL‐18 or resistin levels. Trial Registration: PROSPERO: CRD420251037683 ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420251037683 ).

23 September 2025 in Food Frontiers
Verified
Journal Article
Open access
AZAyesha Zahid
Ayesha Zahid
HIHazrat Ismail
Hazrat Ismail
MAMadiha Ajaz
Madiha Ajaz
AQAbdul Qadeer
Abdul Qadeer
Food allergy, an immune response to food, is a continuously rising and potentially deadly illness that affects millions of people around the globe. The overall immune mechanism of food allergy is described in the context of natural oral tolerance, sensitization, and desensitization. Food allergy management has traditionally focused on strict avoidance of trigger foods and the use of emergency interventions following accidental exposure. However, this approach is evolving with the emergence and development of new therapeutic strategies. Despite the alarming prevalence of food allergies, the Food and Drug Administration (FDA) has, to date, approved only two treatments: Palforzia, an oral immunotherapy for peanut allergy in children, and omalizumab, a monoclonal antibody recently approved as an adjunct therapy for food allergies. However, a growing pipeline of therapeutic options is under development, offering hope for broader and more effective interventions in the near future. This review presents an updated overview of the evolving landscape of interventional therapies for food allergy, spanning past approaches, current strategies, and future directions. It highlights advances in allergen immunotherapy and biologics, including monoclonal antibodies, tyrosine kinase inhibitors, fusion proteins, and immunoglobulin E (IgE)‐disrupting agents, as well as emerging vaccine‐based treatments. Additionally, the review emphasizes recent progress in gut microbiota modulation through approaches such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and bacteriotherapy. Other promising avenues, including the use of nanoparticle‐based therapies, traditional herbal medicines, and dietary supplements, are also discussed as potential therapeutic strategies.

15 February 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MAMadiha Ajaz
Madiha Ajaz
ISIndu Singh
Indu Singh
LVLada Vugic
Lada Vugic
RJRati JANI
Rati JANI
AZAyesha Zahid
Ayesha Zahid
NCNatalie Colson
Natalie Colson
Asthma is a prevalent chronic disease posing substantial health and economic challenges globally. Its progression involves key hallmarks such as inflammation and airway remodeling, mediated by multiple inflammatory biomarkers and pathways. Despite the availability of potent therapeutic options, many patients continue to suffer from uncontrolled asthma. The plasminogen activator inhibitor-1 (PAI-1) signaling pathway is critical in asthma exacerbation and remodeling, with elevated PAI-1 levels linked to disease progression. Anthocyanins (ACNs), potent antioxidants and anti-inflammatory compounds, have shown promise in asthma management. Epidemiological studies associate higher ACN intake with a lower risk of asthma and improved lung function. Preclinical models further demonstrate ACNs’ effectiveness in reducing asthma-related inflammatory cytokines, chemokines, and signaling pathways. Additionally, a human trial suggests ACNs can improve symptom control and lung function. While no direct evidence links ACNs to PAI-1 reduction in asthma, studies in other chronic conditions show ACNs reduce PAI-1 levels, supporting their potential role in asthma. This suggests a promising avenue for exploring their effects on airway remodeling. The lack of robust human studies remains a gap. Future research should focus on establishing direct evidence of ACNs’ impact on PAI-1 levels and remodeling in asthma, providing novel insights into managing asthma as an adjunct.